EMCURE PHARMACEUTICALS L (EMCURE) financials

EMCURE PHARMACEUTICALS L (EMCURE) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1981, Emcure PharmaceuticalsLtd manufactures and markets pharmaceutical products globally[1]

Market Cap: ₹34,539Cr.
Current Price: ₹1,821
Stock P/E: 41.7
ROE: 22.3%
ROCE: 23.7%
Book Value: ₹196
Dividend Yield: 0.20%
52W High / Low: ₹2,101/1,306

In Jun 2026, EMCURE PHARMACEUTICALS L (EMCURE) reported sales ₹1,451 Cr and net profit ₹200 Cr.

Annual TTM: sales ₹5,598 Cr, net profit ₹810 Cr.

Shareholding: Promoters 77.83% (Jun 2026), FIIs 4.87% (Jun 2026), DIIs 8.46% (Jun 2026), Public 8.84% (Jun 2026), No. of Shareholders 1,24,991% (Jun 2026).

EMCURE quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	1,105	1,029	1,278	1,097	1,261	1,418	1,468	1,451
Expenses	947	904	1,034	869	1,036	1,118	1,096	1,111
Operating Profit	158	124	245	228	225	300	372	340
OPM %	14%	12%	19%	21%	18%	21%	25%	23%
Other Income	49	19	22	18	23	109	35	25
Interest	31	20	24	21	28	33	37	33
Depreciation	56	57	57	60	62	62	63	63
Profit before tax	119	67	186	166	158	314	306	269
Tax %	27%	25%	25%	26%	26%	18%	24%	26%
Net Profit	87	50	140	123	118	259	234	200
EPS in Rs	4.60	2.65	7.37	6.48	6.20	13.65	12.33	10.55
Raw PDF	—	—	—	—	—	—	—	—

EMCURE profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	2,376	3,154	3,387	3,107	3,498	4,382	5,243	5,598
Expenses	1,948	2,410	2,593	2,668	3,056	3,759	4,220	4,361
Operating Profit	428	743	795	439	442	623	1,023	1,236
OPM %	18%	24%	23%	14%	13%	14%	20%	22%
Other Income	89	94	133	119	129	142	286	191
Interest	137	123	145	167	166	113	118	131
Depreciation	155	156	166	179	205	225	247	250
Profit before tax	225	557	616	212	200	428	944	1,047
Tax %	22%	25%	28%	25%	20%	26%	22%	—
Net Profit	175	420	447	160	161	317	733	810
EPS in Rs	9.69	23.25	24.71	8.85	8.88	16.74	38.66	42.73
Dividend Payout %	26%	4%	12%	23%	23%	18%	9%	—

EMCURE balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	181	181	181	181	181	181	189	190
Reserves	1,597	1,734	2,121	1,532	1,661	1,754	2,835	3,521
Borrowings	1,224	1,243	1,665	1,579	1,773	1,595	857	1,597
Other Liabilities	576	713	897	1,032	1,001	1,226	1,534	1,607
Total Liabilities	3,578	3,871	4,863	4,323	4,616	4,757	5,416	6,914
Fixed Assets	1,100	1,166	1,278	1,151	1,433	1,718	1,759	1,754
CWIP	406	326	192	239	253	106	99	122
Investments	311	408	864	563	690	684	678	1,424
Other Assets	1,761	1,971	2,529	2,369	2,240	2,248	2,880	3,614
Total Assets	3,578	3,871	4,863	4,323	4,616	4,757	5,416	6,914

EMCURE cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	371	385	775	428	505	585	558	424
Cash from Investing Activity	-276	-169	-836	-394	-271	-173	-438	-947
Cash from Financing Activity	-53	-46	31	-343	-55	-288	-49	526
Net Cash Flow	42	170	-30	-309	180	124	71	3
Free Cash Flow	85	287	677	243	225	342	378	178
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	87%	97%	120%	75%	134%	148%	100%	63%

EMCURE shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	78.08%	77.94%	77.92%	77.92%	77.88%	77.87%	77.87%	77.83%
FIIs	2.91%	3.05%	3.06%	2.86%	3.29%	3.59%	3.35%	4.87%
DIIs	3.96%	3.87%	3.44%	2.84%	4.36%	6.10%	6.10%	8.46%
Public	15.05%	15.15%	15.58%	16.39%	14.46%	12.43%	12.69%	8.84%
No. of Shareholders	1,52,914	1,43,449	1,39,671	1,33,549	1,26,169	1,18,863	1,22,189	1,24,991

EMCURE key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	135	175	116	109	124	115	99	107
Inventory Days	243	200	182	202	214	206	189	197
Days Payable	159	197	168	166	203	220	204	186
Cash Conversion Cycle	220	177	130	144	135	101	84	118
Working Capital Days	50	60	19	17	0	-4	61	53
ROCE %	—	13%	20%	21%	11%	10%	14%	24%

EMCUREUpdated 18 Oct 2026, 5:22

Emcure Pharmaceuticals L

EMCUREUpdated 18 Oct 2026, 5:22

Market Cap

₹34,539Cr.

Current Price

₹1,821

High / Low

₹2,101/1,306

Stock P/E

41.7

ROE22.3%

ROCE23.7%

Book Value₹196

Face Value₹10.0

Dividend Yield0.20%

About

Incorporated in 1981, Emcure PharmaceuticalsLtd manufactures and markets pharmaceutical products globally[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Sep 2023	888	46	788	30	48	36	24	27	1.51
Dec 2023	870	42	746	33	54	61	20	48	2.67
Mar 2024	903	39	796	25	56	35	18	29	1.6
Jun 2024	970	38	855	33	55	55	27	40	2.23
Sep 2024	1105	31	947	49	56	119	27	87	4.6
Dec 2024	1029	20	904	19	57	67	25	50	2.65
Mar 2025	1278	24	1034	22	57	186	25	140	7.37
Jun 2025	1097	21	869	18	60	166	26	123	6.48
Sep 2025	1261	28	1036	23	62	158	26	118	6.2
Dec 2025	1418	33	1118	109	62	314	18	259	13.65
Mar 2026	1468	37	1096	35	63	306	24	234	12.33
Jun 2026	1451	33	1111	25	63	269	26	200	10.55

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2019	2454	127	1883	56	130	370	23	284	15.68
Mar 2020	2376	137	1948	89	155	225	22	175	9.69
Mar 2021	3154	123	2410	94	156	557	25	420	23.25
Mar 2022	3387	145	2593	133	166	616	28	447	24.71
Mar 2023	3107	167	2668	119	179	212	25	160	8.85
Mar 2024	3498	166	3056	129	205	200	20	161	8.88
Mar 2025	4382	113	3759	142	225	428	26	317	16.74
Mar 2026	5243	118	4220	286	247	944	22	733	38.66
TTM	5598	131	4361	191	250	1047	—	810	42.73

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	77.83%
FIIs	4.87%
DIIs	8.46%
Public	8.84%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2024	78.08%	2.91%	3.96%	15.05%
Dec 2024	77.94%	3.05%	3.87%	15.15%
Mar 2025	77.92%	3.06%	3.44%	15.58%
Jun 2025	77.92%	2.86%	2.84%	16.39%
Sep 2025	77.88%	3.29%	4.36%	14.46%
Dec 2025	77.87%	3.59%	6.1%	12.43%
Mar 2026	77.87%	3.35%	6.1%	12.69%
Jun 2026	77.83%	4.87%	8.46%	8.84%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2019	181	1597	1224	576	3578	1100	406	311	1761	3578
Mar 2020	181	1734	1243	713	3871	1166	326	408	1971	3871
Mar 2021	181	2121	1665	897	4863	1278	192	864	2529	4863
Mar 2022	181	1532	1579	1032	4323	1151	239	563	2369	4323
Mar 2023	181	1661	1773	1001	4616	1433	253	690	2240	4616
Mar 2024	181	1754	1595	1226	4757	1718	106	684	2248	4757
Mar 2025	189	2835	857	1534	5416	1759	99	678	2880	5416
Mar 2026	190	3521	1597	1607	6914	1754	122	1424	3614	6914

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2019	371	-276	-53	42
Mar 2020	385	-169	-46	170
Mar 2021	775	-836	31	-30
Mar 2022	428	-394	-343	-309
Mar 2023	505	-271	-55	180
Mar 2024	585	-173	-288	124
Mar 2025	558	-438	-49	71
Mar 2026	424	-947	526	3

Key ratios

Historical financial ratios

Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	135	175	116	109	124	115	99	107
Inventory Days	243	200	182	202	214	206	189	197
Days Payable	159	197	168	166	203	220	204	186
Cash Conversion Cycle	220	177	130	144	135	101	84	118
Working Capital Days	50	60	19	17	0	-4	61	53
ROCE %	—	13%	20%	21%	11%	10%	14%	24%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of EMCURE PHARMACEUTICALS L (EMCURE)?

The reported market capitalisation for EMCURE PHARMACEUTICALS L (EMCURE) is ₹34,539Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of EMCURE?

The current price shown for EMCURE PHARMACEUTICALS L (EMCURE) on Fincrux is ₹1,821 with a 52-week high/low of ₹2,101/1,306.

What is the P/E ratio of EMCURE PHARMACEUTICALS L (EMCURE)?

The stock P/E for EMCURE PHARMACEUTICALS L (EMCURE) is 41.7 on Fincrux, with ROE at 22.3% and ROCE at 23.7%.

What were EMCURE latest quarterly results?

For Jun 2026, EMCURE PHARMACEUTICALS L (EMCURE) reported sales ₹1,451 Cr and net profit ₹200 Cr (figures in ₹ crore unless noted).

What are EMCURE annual sales and net profit?

For TTM, EMCURE PHARMACEUTICALS L (EMCURE) shows sales of ₹5,598 Cr and net profit of ₹810 Cr on the Fincrux profit & loss statement.

Who owns EMCURE PHARMACEUTICALS L (EMCURE)?

Latest shareholding for EMCURE PHARMACEUTICALS L (EMCURE) on Fincrux: Promoters 77.83% (Jun 2026), FIIs 4.87% (Jun 2026), DIIs 8.46% (Jun 2026), Public 8.84% (Jun 2026), No. of Shareholders 1,24,991% (Jun 2026).

Where can I find EMCURE PHARMACEUTICALS L (EMCURE) financials?

EMCURE PHARMACEUTICALS L (EMCURE) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show EMCURE balance sheet and cash flow?

Yes. The EMCURE PHARMACEUTICALS L (EMCURE) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 5:22